REACTing (REsearch and ACTion targeting emerging infectious diseases)

Inserm and its Aviesan partners have created REACTing, a multidisciplinary consortium that brings together research groups and laboratories of excellence in order to prepare for and coordinate research to combat the health crises linked to emerging infectious diseases.

COVID-19: 20 research projects selected to fight the outbreak

As the coronavirus Sars-CoV2 outbreak continues to spread, the Alliance for Life Sciences and Health (Aviesan) is working to accelerate research on the virus and on the disease COVID-19 through the action of the REACTing consortium, coordinated by Inserm. With the support of the Ministry of Solidarity and Health and the Ministry of Higher Education, Research and Innovation, 20 scientific initiatives have been selected by the REACTing scientific council. They cover themes as diverse as epidemic modelling, treatment research and prevention.

To find out more about these initiatives:

H5N1 and H1N1 flu, SARS, MERS-CoV, Chikungunya, Ebola, and Zika: our societies are regularly confronted with local and global health crises linked to an emerging infection of viral or bacterial origin. In order to be better prepared for these crises, Inserm and its Aviesan partners have created REACTing (REsearch and ACTion targeting emerging infectious diseases).

This multidisciplinary consortium brings together high-quality French research groups. It does not focus on any particular disease and may work on any emerging infection, particularly zoonotic infections. It has a wide scope of action, from fundamental research to the social sciences and humanities, with a cross-cutting approach emphasized throughout. The consortium is led by the Immunology, Inflammation, Infectiology and Microbiology Institute.

Inserm’s commitments to REACTing are as follows:

  • to improve the readiness of research between crisis periods through: governance, preparation of research tools, identifying research priorities, research funding, and in particular ethical and legal preparation, as these aspects are crucial in preparing for research projects that need to coalesce urgently;
  • to fund and implement research projects in a period of epidemic crisis through: coordination, strategic priorities, methodological assistance, and providing information to the authorities and the general public.

Visit the REACTing Consortium website


Coordinated by Inserm, the ZIKAlliance is leading a large-scale research project into Zika virus infection. This multidisciplinary and multinational research consortium is funded by the European Union research and innovation program Horizon 2020, under funding agreement no. 734548. It has been allocated a budget of 12 million euros over 3 years.

The consortium is led by the virologist Xavier de Lamballerie (Inserm, IRD, Université Aix-Marseille). It includes 52 partners, located across 18 different countries. In France, 11 partners are working alongside Inserm on this project: the Institut Pasteur in Paris and in New Caledonia, Inserm Transfert, IRD, CEA, CNRS, Aix-Marseille Université, Institut Louis Malardé (Papeete), French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Université de Lyon, and Université de Rennes 2. The main European research institutions will contribute to the fundamental research programs. Partners in Africa, Asia, and in Polynesia will take part in intercontinental epidemiological studies planned by the ZIKAlliance.

To find out more, read the press release: Global consortium receives €12 million to combat the Zika virus (October 24, 2016)